Hepatitis D Market Report 2026

The hepatitis d market size has grown steadily in recent years. It will grow from $0.76 billion in 2025 to $0.79 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to improved hepatitis B screening coverage, increased recognition of HDV severity, expansion of diagnostic capabilities, rising referral to specialty centers, availability of targeted therapies.

The hepatitis d market size is expected to see steady growth in the next few years. It will grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing research into novel HDV treatments, rising focus on combination antiviral therapies, expansion of vaccination-linked prevention strategies, growing awareness in high-risk populations, increased investments in rare liver disease research. Major trends in the forecast period include increasing focus on early detection of co-infections, rising use of advanced serologic testing, growing demand for specialized treatment protocols, expansion of hospital-based disease management, enhanced focus on disease awareness.

The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can progress to chronic liver disease or liver cancer if untreated. The increase in hepatitis B cases is linked to unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and inadequate vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, as it uses the surface antigen of hepatitis B to infect liver cells, making co-infection a critical factor in liver disease progression. For example, according to the Department of Health and Human Services, a US government agency, 17,650 new chronic hepatitis B cases and 1,769 hepatitis B-related deaths were reported in 2023. Therefore, the increasing prevalence of hepatitis B is driving the hepatitis D market.

Key companies in the hepatitis D market are focusing on innovative solutions such as RNA-targeted antiviral therapies to improve treatment outcomes and address unmet medical needs in chronic hepatitis D infection. RNA-targeted antiviral therapy is designed to directly target viral RNA, inhibiting replication, disrupting protein production, or silencing viral genes, thereby reducing viral load and controlling infection. For instance, in December 2024, Vir Biotechnology Inc., a US-based biotech company, received both the FDA Breakthrough Therapy designation and the EMA PRIME designation for its combination therapy of tobevibart and elebsiran for treating chronic hepatitis delta (CHD).

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation therapeutics. The collaboration aims to create innovative antiviral treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc., a US-based biotechnology firm, specializes in developing small-molecule therapeutics targeting serious viral diseases, primarily hepatitis B and herpesviruses.

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.

North America was the largest region in the hepatitis D market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis d market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis d market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hepatitis D market by increasing costs of imported diagnostic reagents, antiviral medications, and laboratory equipment used for disease detection and monitoring. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported diagnostic technologies, while Asia-Pacific faces cost pressure on testing infrastructure. These tariffs are increasing diagnostic expenses and slowing testing expansion. However, they are also encouraging local production of diagnostic kits and strengthening regional laboratory manufacturing capabilities.

The hepatitis d market research report is one of a series of new reports that provides hepatitis d market statistics, including hepatitis d industry global market size, regional shares, competitors with a hepatitis d market share, detailed hepatitis d market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis d industry. This hepatitis d market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis D, also called hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is considered the most severe form of viral hepatitis and occurs only in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on hepatitis B virus for replication and survival, making it a co-infection or superinfection.

The main types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by HDV, often leading to rapid-onset symptoms and potential liver complications. Diagnosis involves blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Drugs for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end-users such as clinics, hospitals, and other healthcare facilities.

The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.